AngioDynamics Posts Wider Q3 Loss On Higher Costs, Reaffirms FY22 Outlook
AngioDynamics Inc (NASDAQ:ANGO) has reported a Q3 FY22 adjusted EPS of $0.03, ahead of the consensus of $(0.01), and better than the consensus of $0.02 reported a year ago. Q3 sales increased 3.9% Y/Y to $73.97 million, missing the analyst consensus of $76.32 million. Endovascular Therapies net sales increased 14.5% to $38.1…
Benzinga ·
Benzinga
